How much cash does Beta Bionics, Inc. Common Stock generate?

Beta Bionics, Inc. Common Stock (BBNX) generated -$54.8M in operating cash flow over the trailing twelve months.

What is Beta Bionics, Inc. Common Stock's free cash flow?

After $6.3M of capital expenditures, Beta Bionics, Inc. Common Stock's free cash flow was -$61.1M over the trailing twelve months, down 2.9% year over year.

Where does Beta Bionics, Inc. Common Stock's cash flow data come from?

Every line is extracted from Beta Bionics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Beta Bionics, Inc. Common Stock BBNX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$21.9M-62.6%	-$13.47M+5.2%	-$14.21M+15.8%	-$16.87M+41.1%	-$28.66M-58.3%
Depreciation and amortization	$585K+8.7%	$538K+39.7%	$385K+11.0%	$347K+14.5%	$303K+30.6%
Stock-based compensation	$5.41M+25.6%	$4.3M-3.9%	$4.48M-6.7%	$4.8M+71.1%	$2.8M+80.7%
Provision for credit losses	——	$16K-33.3%	$24K—	$0—	$0-100%
Change in accounts receivable	-$1.37M-124%	$5.6M—	——	——	-$2.94M-164%
Change in inventories	$1.8M-18.2%	$2.2M-33.8%	$3.33M+92.4%	$1.73M-34.0%	$2.62M+117%
Change in accounts payable	-$3.33M-732%	$527K-52.1%	$1.1M+93.7%	$568K+686%	-$97K—
Change in accrued liabilities	-$5.22M-189%	$5.86M+42.4%	$4.12M+51.1%	$2.72M+152%	-$5.27M-248%
Change in other assets	$1K—	——	$39K+2,050%	-$2K+50.0%	-$4K—
Change in other liabilities	$11K-96.8%	$342K+76.3%	$194K—	——	——
Change in deferred revenue	$201K-61.8%	$526K+1.7%	$517K-2.8%	$532K+10.8%	$480K-38.7%
Non-cash operating lease expense	$402K+1.3%	$397K+33.2%	$298K-2.6%	$306K+1.7%	$301K+1.3%
Change in operating lease liabilities	-$391K-1.8%	-$384K-34.7%	-$285K+0.3%	-$286K-1.8%	-$281K-2.9%
Debt issuance costs and discount amortization	$86K—	——	——	——	-$916K—
Net cash from operating activities	-$23.83M-176%	-$8.63M+1.2%	-$8.73M+35.8%	-$13.59M+31.9%	-$19.98M-39.9%
Capital expenditures	$1.38M-27.6%	$1.9M+48.4%	$1.28M-27.9%	$1.78M+434%	$333K-40.6%
Purchases of investments	——	$45.26M-1.6%	$46M-3.8%	$47.83M-66.5%	$142.94M+217%
Proceeds from maturities/sales of investments	$48M0.0%	$48M-32.4%	$71M+209%	$23M-17.9%	$28M+75.0%
Proceeds from sale of property, plant and equipment	——	——	——	——	——
Purchases of other investments	$24.78M+13,982%	$176K-98.8%	$14.23M—	——	$63.85M—
Net cash from investing activities	$21.84M—	——	——	——	-$179.12M-504%
Proceeds from issuance of common stock	$623K—	——	——	——	$195.43M+528,089%
Payment of debt issuance costs	——	——	——	——	——
Proceeds from issuance of preferred stock	——	——	——	——	——
Net cash from financing activities	$623K-41.2%	$1.06M-60.0%	$2.65M+6,217%	$42K-100.0%	$211.12M+271%
Net increase (decrease) in cash	-$1.37M—	——	$3.41M—	——	$12.02M-7.2%
Amortization Of Debt Discount Premium	$86K—	——	——	——	-$916K—
Depreciation	$585K+8.7%	$538K+39.7%	$385K+11.0%	$347K+14.5%	$303K+30.6%
Accrued expenses and other liabilities	-$5.22M-189%	$5.86M+42.4%	$4.12M+51.1%	$2.72M+152%	-$5.27M-248%
Deferred revenue	$201K-61.8%	$526K+1.7%	$517K-2.8%	$532K+10.8%	$480K-38.7%
Operating lease liabilities	-$391K-1.8%	-$384K-34.7%	-$285K+0.3%	-$286K-1.8%	-$281K-2.9%
Other long-term liabilities	$11K-96.8%	$342K+76.3%	$194K—	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	-$951K-330%	$413K-76.9%	$1.79M-9.8%	$1.99M+22.5%	$1.62M+43.6%
Operating lease right-of-use asset amortization	$402K+1.3%	$397K+33.2%	$298K-2.6%	$306K+1.7%	$301K+1.3%
Provision For Excess And Obsolete Inventory	-$202K-124%	$854K+96.3%	$435K—	$0-100%	$211K+126%
Payments to Acquire Long-Term Investments	$24.78M+13,982%	$176K-98.8%	$14.23M—	——	$63.85M—
Payments to Acquire Short-Term Investments	——	$45.26M-1.6%	$46M-3.8%	$47.83M-66.5%	$142.94M+217%
Proceeds from Maturities, Prepayments and Calls of Short-Term Investments	$48M0.0%	$48M-32.4%	$71M+209%	$23M-17.9%	$28M+75.0%
Payments Of Stock Issuance Costs	——	——	——	——	——
Proceeds From Issuance Of Convertible Preferred Stock	——	——	——	——	——
Common stock issuance for private placement	——	——	——	——	$15.59M—
Proceeds From Warrant Exercises	——	——	——	——	——
Conversion Of Convertible Preferred Stock Upon Initial Public Offering	——	——	——	——	$321.37M—
Conversion Of Warrants Net Exercise Upon Initial Public Offering	——	——	——	——	$57.35M—
Fair Value Adjustment Of Warrants	$0—	$0—	$0—	$0-100%	$12.45M+107%
Increase Decrease In Operating Lease Liability	-$391K-1.8%	-$384K-34.7%	-$285K+0.3%	-$286K-1.8%	-$281K-2.9%
Reclassification Of Deferred Offering Costs To Equity Upon Initial Public Offering	——	——	——	——	$5.05M—
Reclassification Of Long Term Investments To Short Term Investments	$30.15M-33.4%	$45.26M-1.6%	$46M—	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	$3.83M+1,586%
Free cash flow	-$25.21M-139%	-$10.53M-5.2%	-$10.01M+34.9%	-$15.37M+24.3%	-$20.31M-36.8%
Free cash flow	-$25.21M-139%	-$10.53M-5.2%	-$10.01M+34.9%	-$15.37M+24.3%	-$20.31M-36.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Beta Bionics, Inc. Common Stock.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Beta Bionics, Inc. Common Stock generate?: Beta Bionics, Inc. Common Stock (BBNX) generated -$54.8M in operating cash flow over the trailing twelve months.
What is Beta Bionics, Inc. Common Stock's free cash flow?: After $6.3M of capital expenditures, Beta Bionics, Inc. Common Stock's free cash flow was -$61.1M over the trailing twelve months, down 2.9% year over year.
Where does Beta Bionics, Inc. Common Stock's cash flow data come from?: Every line is extracted from Beta Bionics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.